Columbia Seligman Premium Technology Growth Fund STK
At closeNov 3, 2026, 4:00 PM EST
After hours · Nov 3, 4:00 PM ET
- YTD
- +39.09%
- 1 year
- +29.32%
- Market cap
- 905.46M
- EPS (ttm)
- 30.27
- Shares out
- 16.58M
- P/E ratio
- 1.69
- Dividend
- 1.85 (7.03%)
- Ex-dividend date
- Aug 10, 2023
- YTD return
- +39.09%
- 1-year return
- +29.32%
- Volume
- 33.58K
- Avg volume
- 51.44K
- Open
- 50.99
- Previous close
- 50.69
- Day's range
- 50.96 – 52.65
- 52-week range
- 32.50 – 58.46
2Y +18.66 (+57.45%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 7.03%
- Payout ratio
- 34.07%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 33.61
- 200-day average
- 32.57
Next earnings
Consensus EPS estimate 0.00.
About Columbia Seligman Premium Technology Growth Fund
Columbia Seligman Premium Technology Growth Fund is a closed ended equity mutual fund launched and managed by Columbia Management Investment Advisers, LLC. It invests in public equity markets. The fund seeks to invest in stocks of companies operating in the technology sector. It primarily invests in growth stocks of companies. It employs fundamental analysis with focus on factors like companies that have best growth prospects, trade at attractive valuations and deliver solid investment returns over time to create its portfolio. The fund benchmarks the performance of its portfolio against the S&P North American Technology Sector Index. The fund was formerly known as Seligman Premium Technology Growth Fund, Inc. Columbia Seligman Premium Technology Growth Fund was formed on November 30, 2009 and is domiciled in the United States.
- Sector
- Financial Services
- Industry
- Asset Management
- Country
- United States
News
A Fistful Of Magnificent CEFs 
STK Vs. TDVI: The Unicorn CEF And Its Closest ETF Equivalent 
Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting 
Columbia Seligman Premium Technology Growth Fund Announces a Fourth Quarter Distribution: 9.25% Annual Rate for IPO Investors 
Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting 
How To Potentially Retire In Your 40s 
STK: This Tech CEF Is Crushing QQQ, And Is Still Trading At A Discount 
AI Is Not A Bubble: 4 Income Ideas To Ride The Wave 
Columbia Seligman Premium Technology Growth Fund Announces a Third Quarter Distribution: 9.25% Annual Rate for IPO Investors 
10 Funds For Potential $6,000 Monthly Income: Retirement Series
Your note
Sign in to keep a note on STK — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Wells Fargo & Company | 2.17% | 359,749 | 11.45M | Sep 29, 2024 |
| Royal Bank of Canada | 1.87% | 309,304 | 9.85M | Sep 29, 2024 |
| Morgan Stanley | 1.63% | 270,703 | 8.62M | Sep 29, 2024 |
| Janney Montgomery Scott LLC | 1.55% | 256,711 | 8.17M | Sep 29, 2024 |
| Invesco Ltd. | 0.90% | 149,118 | 4.75M | Sep 29, 2024 |
| LPL Financial LLC | 0.72% | 119,770 | 3.81M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Invesco ETF Tr II-Invesco Income Composite ETF | 0.70% | 116,387 | 3.70M | Oct 30, 2024 |